|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||||||||||
| Investments: | ||||||||||||||||||||
| Investments, available for sale: | ||||||||||||||||||||
| Fixed maturities, at fair value (amortized cost $74,253,192 and $74,900,990) | ||||||||||||||||||||
| Held to maturity redeemable preferred stock, at amortized cost | ||||||||||||||||||||
| Held to maturity redeemable preferred stock, at amortized cost | ||||||||||||||||||||
| Equity securities, at fair value (cost $91,366,652 and $89,387,893) | ||||||||||||||||||||
| Equity securities, at fair value (cost $124,179,844 and $127,220,244) | ||||||||||||||||||||
| Equity securities, at cost | ||||||||||||||||||||
| Mortgage loans on real estate, at amortized cost (net of credit loss reserve of $410,000 and $220,000) | ||||||||||||||||||||
| Investment real estate, net | ||||||||||||||||||||
| Notes receivable (net of credit loss reserve of $70,000 and $135,000) | ||||||||||||||||||||
| Policy loans | ||||||||||||||||||||
| Short-term investments | ||||||||||||||||||||
| Total investments | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Accrued investment income | ||||||||||||||||||||
| Reinsurance receivables: | ||||||||||||||||||||
| Future policy benefits | ||||||||||||||||||||
| Policy claims and other benefits | ||||||||||||||||||||
| Cost of insurance acquired | ||||||||||||||||||||
| Income tax receivable | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| LIABILITIES AND SHAREHOLDERS' EQUITY | ||||||||||||||||||||
| Policy liabilities and accruals: | ||||||||||||||||||||
| Future policyholder benefits | ||||||||||||||||||||
| Policyholder account balances | ||||||||||||||||||||
| Policy claims and benefits payable | ||||||||||||||||||||
| Other policyholder funds | ||||||||||||||||||||
| Dividend and endowment accumulations | ||||||||||||||||||||
| Income taxes payable | ||||||||||||||||||||
| Deferred income taxes | ||||||||||||||||||||
| Notes payable | ||||||||||||||||||||
| Trading securities, at fair value (proceeds $0 and $0) | ||||||||||||||||||||
| Other liabilities | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Shareholders' equity: | ||||||||||||||||||||
| Common stock - no par value, stated value $0.001 per share. Authorized 7,000,000 shares - 3,136,826 and 3,142,470 shares outstanding | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Retained earnings | ||||||||||||||||||||
| Accumulated other comprehensive income | ||||||||||||||||||||
| Total UTG shareholders' equity | ||||||||||||||||||||
| Noncontrolling interest | ||||||||||||||||||||
| Total shareholders' equity | ||||||||||||||||||||
| Total liabilities and shareholders' equity | ||||||||||||||||||||
Loading...
